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ABSTRACT  
 
Although mitochondrial dysfunction is a consistent feature of Alzheimer's disease (AD) in the brain and 
blood, the molecular mechanisms behind these phenomena are unknown. Here we have replicated our 
previous findings demonstrating reduced expression of nuclear-encoded oxidative phosphorylation 
(OXPHOS) subunits and subunits required for the translation of mitochondrial-encoded OXPHOS genes 
in blood from people with AD and mild cognitive impairment (MCI). Interestingly this was 
accompanied by increased expression of some mitochondrial-encoded OXPHOS genes, namely those 
residing closest to the transcription start site of the polycistronic heavy chain mitochondrial transcript 
(MT-ND1, MT-ND2, MT-ATP6, MT-CO1, MT-CO2, MT-C03) and MT-ND6 transcribed from the 
light chain. Further we show that mitochondrial DNA copy number was unchanged suggesting no 
change in steady-state numbers of mitochondria. We suggest an imbalance in nuclear and mitochondrial 
genome-encoded OXPHOS transcripts may drive a negative feedback loop reducing mitochondrial 
translation and compromising OXPHOS efficiency, which is likely to generate damaging reactive 
oxygen species (ROS). 
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There are an estimated 35.6 million cases of dementia worldwide which is likely to treble by 2050 due 
to an increasingly aging population (Prince and Jackson, 2009). Alzheimer’s disease (AD), the most 
common form of dementia, is characterized by slow progressive loss of cognition and development of 
behavioral and personality problems associated with neuronal cell loss. Within the brain, there is an 
accumulation of insoluble extracellular plaques consisting of aggregated amyloid-β (Aβ) and 
intracellular neurofibrillary tangles of hyperphosphorylated Tau. Their generation is believed to lead to 
the disruption of calcium homeostasis (LaFerla, 2002), collapse of neuronal synapses and loss of 
connectivity (Terry et al., 1991), increased production of reactive oxygen species (ROS), oxidative 
damage (Nunomura et al., 2001) and a damaging inflammatory response (Hanisch and Kettenmann, 
2007) in vulnerable brain regions. Although much progress has been made we still lack a full 
understanding of the molecular pathology of AD, thus the treatments currently available only 
temporarily alleviate some symptoms and do not modify the underlying causes.  
 
Mitochondria are key providers of energy to the cell in the form of ATP through oxidative 
phosphorylation (OXPHOS). OXPHOS requires 97 proteins to assemble in five multi-protein complexes 
in the correct stoichiometry for a functioning supramolecular complex (Chaban et al., 2014). 84 
OXPHOS genes are encoded by the nuclear genome, whilst an additional 13 (complexes I, III, IV and 
V) are expressed as polycistronic RNAs from three mitochondrial DNA (mtDNA) promoter regions 
(HSP1, HSP2 and LSP1) (Kyriakouli et al., 2008). Mitochondrial gene expression is tightly controlled. 
 
OXPHOS dysfunction can produce ROS and oxidative stress leading to neuronal cell death in aging and 
















levels of many subunits within this complex leading to a reduction in overall complex activity (Bosetti et 
al., 2002; Kish et al., 1992; Maurer et al., 2000; Mutisya et al., 1994; Valla et al., 2001). APP, Aβ and 
APOE have all been shown to accumulate in neuronal mitochondrial membranes (Devi et al., 2006; 
Manczak et al., 2004) and either through direct binding to OXPHOS proteins, or indirect mechanisms 
have been shown to perturb mitochondrial energy balance (Manczak et al., 2006). Even in the early 
stages of disease, prior to a clinical diagnosis of AD, many of the nuclear genes encoding subunits 
involved in OXPHOS are down-regulated in the brains of people with mild cognitive impairment (MCI) 
particularly in those brain regions most vulnerable to AD pathology such as the hippocampus and cortex 
(Liang et al., 2008; Manczak et al., 2004). People with MCI are considered to be in the symptomatic 
pre-dementia phase of AD, displaying cognitive impairment beyond what is expected for their age, but 
not severe enough to affect their function and are thus not considered to have dementia at that point in 
time. Many people with MCI will progress to AD, particularly those with high levels of AD pathology 
markers (Jack et al., 2016). 
 
Similar OXPHOS changes and markers of oxidative damage in AD brain appear to be mirrored in the 
periphery including in platelets (Bosetti et al., 2002; Cardoso et al., 2004; Parker et al., 1990; Valla et 
al., 2006) and white blood cells from AD patients (Feldhaus et al., 2011; Lunnon et al., 2012; Lunnon et 
al., 2013; Mecocci et al., 2002; Mecocci et al., 1998; Sultana et al., 2013; Sultana et al., 2011; Wang et 
al., 2006). We previously observed a significant reduction in OXPHOS gene expression in white blood 
cells, even in subjects with MCI, many of whom were subsequently found to have prodromal AD 
(Lunnon et al., 2012). Some of these changes were capable of distinguishing AD and MCI subjects from 
elderly controls as part of a biomarker panel (Booij et al., 2011; Lunnon et al., 2013). In the current 
study, we have sought to replicate these findings and establish if they represent a decrease in steady-
















understanding the mechanism behind these changes and thus the context in which they could be used as 
a biomarker for testing the efficacy of drugs targeting AD. 
 
First, we found that nuclear genome-encoded OXPHOS transcripts are down-regulated in MCI and AD 
blood. Second, we analyzed mitochondrial genome-encoded OXPHOS subunits to see if they were also 
decreased in a similar way to the nuclear-genome OXPHOS subunits, which might point to a change in 
mitochondrial biogenesis or mitophagy. Finally we measured the relative abundance of mtDNA to 
nuclear DNA to establish if there was an alteration in mitochondrial steady-state levels or whether the 
changes we observed were more likely to represent a reduction in cellular respiratory chain activity. 
 
2.0 MATERIALS AND METHODS 
2.1 Subjects and Samples 
Blood samples for DNA and RNA analyses were taken from subjects participating in two biomarker 
studies coordinated from the Institute of Psychiatry, Psychology & Neuroscience, King’s College 
London; The AddNeuroMed (ANM) study and the Maudsley Biomedical Research Center (BRC) 
Dementia Case Register (DCR) curated by the National Institute for Health Research (NIHR) 
Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust 
and King’s College London. Full details on sample collection and assessment are supplied in the 
Supplementary Methods. Subject characteristics are summarized in Table 1. 
 
2.2 RNA extraction 
Whole blood samples were collected in PAXgene tubes (BD Diagnostics) and stored at -80°C until RNA 
extraction.  Total RNA was extracted, quantified and quality assessed as previously described (Lunnon 

















2.3 Analysis of nuclear-encoded OXPHOS genes using BeadArrays 
Total RNA was converted to cDNA (200ng) and then biotinylated cRNA according to the protocol 
supplied with the Illumina TotalPrep-96 RNA Amplification Kit (Ambion). Previously we studied 
disease pathway changes in AD, MCI and control subjects by hybridizing blood RNA to Illumina HT-12 
V3 (Lunnon et al., 2012), which is deposited  in the Gene Expression Omnibus (GEO) (Batch 1, GEO 
accession number GSE63060). For the current study we used an independent set of subject samples that 
were hybridized to Illumina HT-12 V4 according to the manufacturer’s protocol (Batch 2, GEO 
accession number GSE63061). Gene expression values were obtained using Genome Studio (Illumina). 
Pre-processing and analysis of data quality including background correction and normalization were 
performed in R using the Bioconductor packages, Lumi (Gonzalez de Aguilar et al., 2008), MBCB 
(Allen et al., 2009) and SVA (Leek et al., 2012). BeadChips with a very low detection rate (<80%), or a 
discrepancy in XIST and/or EIF1AY gene expression with recorded gender were removed from further 
analyses, leaving 370 Batch 2 samples available for analysis. 240 probes on the array corresponded to 
genes coding for OXPHOS-related proteins: 110 OXPHOS protein subunits, 10 probes encoding genes 
required for mitochondrial transcription and 120 mitochondrial ribosome protein subunits (MRP) 
involved in mitochondrial translation. Of these, 225 probes passed quality control within the Lumi 
package and were carried forward to analysis (Table 2). 
 
The effects of age, gender, collection site and RIN were regressed out of the data and the corresponding 
residuals were compared between diagnostic groups (control, MCI and AD) using linear models 
followed by post-hoc t-tests. In line with our previous beadchip data (Lunnon et al., 2012), probes were 
deemed to be differentially expressed if FDR q<0.01 (Benjamini and Hochberg, 1995). A Fisher's exact 
















our previously published dataset (Lunnon et al., 2012) (Batch 1) and data from the new validation cohort 
(Batch 2), while a chi-squared test was used to compare the number of significant probes between 
OXPHOS complexes. 
 
2.4 Analysis of mitochondrial genome-encoded OXPHOS transcripts using qRT-PCR 
Genes from the mitochondrial genome are not assayed on Illumina HT-12 V4 Expression Beadarrays. 
Therefore, specific primers targeting the 13 mitochondrial OXPHOS genes were designed for use in 
qRT-PCR (Table S1). cDNA was synthesized from 250ng of total RNA using the QuantiTect Reverse 
Transcription Kit (Qiagen) and diluted five-fold for PCR. Real time PCR was performed with 5x HOT 
FIREPol® EvaGreen®qPCR Mix Plus (ROX) (SolisBiodyne). The copy number of each sample was 
generated from comparison to a standard curve which was further normalized using the geometric mean 
of the housekeeping genes ATP5B and SF3A1 (Primer Design Ltd, UK), which we identified as the 
most stable of twelve routine housekeeping genes, using the Normfinder application. Data was 
transformed to achieve a parametric distribution and the effects of age, gender, collection site and RIN 
were regressed out of the data within R, and residuals compared between diagnostic groups using linear 
models, with p-values adjusted for multiple testing (Benjamini and Hochberg, 1995). Genes were 
deemed to be differentially expressed if FDR q<0.01. Further details are provided in the supplementary 
methods. 
 
2.5 Analysis of OXPHOS protein subunits using Luminex 
Briefly, buffy coat samples were lysed using red cell lysis buffer, followed by centrifugation and 
removal of the supernatant. The pellet was resuspended in 300 µl of Cell/Mitochondria Lysis Buffer 
(Human Oxidative Phosphorylation Magnetic Bead Panel), pre-mixed with an EDTA-free Protease 
















for 20 min at 4°C. The concentration of protein in the supernatant was measured using the Nanodrop 
1000 Spectrophotometer (Thermo Fisher Scientific). 
 
The MILLIPLEX®MAP Kit Human Oxidative Phosphorylation (OXPHOS) Magnetic Bead Panel was 
used according to the manufacturer’s protocol (EMD, Millipore). This 6-plex immunoassay measures 
key proprietary subunits in complexes I to V. Data from each sample were normalized using 
Nicotinamide nucleotide transhydrogenase (NNT) measured in the same assay. Data was log 
transformed and technical outliers >2 standard deviations from the mean were removed. The effects of 
age, gender and collection site were regressed out of the data within R, and residuals were compared 
between diagnostic groups using linear models, with post-hoc t-tests. Further details are provided in the 
Supplementary Methods 
 
2.6 Analysis of mitochondrial DNA (mtDNA) copy number using qRT-PCR 
Total genomic DNA was prepared (Qiagen blood DNA kit) from 100 µl of whole blood collected in 
EDTA-coated vacutainer tubes. It was pretreated by sonication prior to extraction and DNA extracted 
according to the manufacturers protocol (Qiagen blood DNA kit). Samples were assayed in triplicate 
using the QuantiTectTM SYBRgreen PCR kit (Qiagen), using primers complementary to unique regions 
and genes of the mitochondrial genome (thus not amplifying NUMTs) and the single copy nuclear gene 
Beta 2 microglobin (B2M) in the presence of reference standards, as previously described (Malik et al., 
2009). Mitochondrial DNA content was quantified as the ratio of mitochondrial genome to nuclear 
genome. Data was log transformed and the effects of age, gender and collection site regressed out within 
R. Corresponding residuals were compared between diagnostic groups (control, MCI and AD) using 


















3.1 Reduced expression of nuclear-encoded OXPHOS genes 
We previously demonstrated reduced expression of a significant number of nuclear OXPHOS genes and 
mitochondrial ribosome protein subunits (MRP genes) in MCI and AD blood compared to controls 
(Lunnon et al., 2012) (Batch 1). We have replicated and extended these findings in a further independent 
group of 370 individuals in the current study (Batch 2; Table 2). There was a significantly high degree 
of overlap in the genes found to be differentially expressed and their direction of change between control 
and MCI/AD subjects between the two cohorts (FDR q<0.01) (Table S2) with 34/99 complex I to 
complex IV probesets and 24/117 mitochondria ribosome protein subunits significantly altered in 
disease compared to 44/99 and 26/118, previously. As expected, the majority of these genes had lower 
expression in MCI/AD relative to age-matched controls. The number of probes reaching q<0.01 within 
each OXPHOS complex was similar between the two datasets (Table S3). Decreased expression was not 
biased to any particular complex in either this dataset (X2 (5.044, 4), p=0.228), or the previously 
published dataset (X2 (4.195, 4), p=0.380). 
 
3.2 Increased expression of mitochondrial-encoded OXPHOS genes 
Having shown further evidence for decreased expression of many of the nuclear-encoded OXPHOS 
genes and protein subunits of the mitochondrial ribosome required for translation of OXPHOS genes 
from the mitochondrial genome in AD and MCI, we were interested to see if this impacted on OXPHOS 
subunits expressed from the mitochondrial genome required for complex I, III, IV and V. Of the 13 
OXPHOS genes encoded by the mitochondria, we were able to successfully quantify 12 using qRT-PCR 
(Figure 1, Table 3, Figure S1). Unlike nuclear-encoded genes, the mitochondrial-encoded genes 
displayed significantly increased levels of expression in MCI and AD blood relative to controls in one of 
















mtDNA complex IV genes, MT-CO1 (F (36.45, 501), p=3.05x10-9, q=3.66x10-8), MT-CO2 (F (21.04, 
501), p=5.69x10-5, q=2.28x10-5) and MT-CO3 (F (9.48, 505), p=2.19x10-3, q=5.26x10-3), and, the only 
mtDNA complex V gene assayed, MT-ATP6 (F (21.88, 500), p=3.73x10-6, q=2.24x10-5). We also 
observed significantly increased expression of MT-ND2 (p=5.1x10-4; q=1.67x10-3), MT-ND5 
(p=2.4x10-3; q=6.43x10-3) and MT-ND6 (p=2.40x10-7; q=8.64x10-6) from complex 1 in MCI subjects, 
following a post hoc t-test. 
 
3.3 Changes in gene expression do not reflect altered mtDNA copy number 
Having identified an overall increase in the level of expression in many of the mitochondrial genes, we 
were keen to establish whether the net effect of the changes we observed are likely to represent altered 
mitochondrial biogenesis or mitophagy, or altered OXPHOS efficiency at the individual mitochondrial 
level. No difference in the copy number of mtDNA was found between control, MCI and AD groups for 
those subjects where blood was available for assessment (Figure S2) (F (1.857), p=0.1766) on 1 and 85 
degrees of freedom, with between group t-tests (corrected for false discovery rate (FDR) (Benjamini and 
Hochberg, 1995)): control versus MCI p = 0.27; control versus AD p = 0.27; MCI versus AD p = 0.94. 
 
3.4 Changes in gene expression are not associated with alteration in protein markers of OXPHOS 
complexes I to V 
Having identified a significant decrease in many nuclear-encoded OXPHOS genes alongside an increase 
in many of the mitochondrial-encoded OXPHOS genes, we wanted to assess the potential impact on the 
profiles of different OXPHOS complexes. The results of a Human OXPHOS Magnetic Bead Panel 
showed a significant decrease in the level of Complex I between groups (p=0.045), reflecting lower 
















nominal significance once multiple testing correction was applied (q=0.224 and q=0.570, respectively). 
There were no differences in the levels of other complexes with disease. 
 
4.0 DISCUSSION 
Our results have confirmed and extended previous findings of a perturbed mitochondrial OXPHOS 
system in blood cells from people with MCI and in AD platelets (Bosetti et al., 2002; Cardoso et al., 
2004; Feldhaus et al., 2011; Lunnon et al., 2012; Lunnon et al., 2013; Mecocci et al., 2002; Mecocci et 
al., 1998; Parker et al., 1990; Sultana et al., 2013; Sultana et al., 2011; Valla et al., 2006; Wang et al., 
2006). Complexes I, IV and V appear to be particularly vulnerable with ~25%, ~30% and ~50%, of 
nuclear genes, respectively, having reduced expression while ~14%, 100% and 100%, of mitochondrial 
genome genes, respectively, have increased expression in MCI or AD blood relative to controls, which 
is predicted to be due to a block in their translation. The changes we report are already evident in people 
with MCI, many of whom are expected to have prodromal disease (Gauthier et al., 2006) and significant 
AD pathology (Albert, 2011). The magnitude of differential expression in OXPHOS genes was greater 
in people with an AD diagnosis compared to those with MCI, which either reflects the relative mildness 
of pathology in MCI, or that not all people with MCI have AD pathology. We are unable to establish 
from the present study which of the different AD pathological biomarkers these changes may be most 
closely associated with. 
 
Some of these changes appear to have culminated in changes at the protein level; there was a trend 
towards lower abundance of the protein marker highly correlated with the functional activity of 
Complex I in AD blood. However, this modest change failed to reach nominal significance after 
correction for multiple testing, possibly because far fewer samples were available for protein analysis 
















with altered expression, this did not translate in to a change at the protein level in those with disease. 
Few studies have explored the association between OXPHOS gene expression and functional read-outs. 
However, at least in one study there is modest association between levels of OXPHOS gene expression 
and mitochondrial membrane potential, viability, ATP, MTT and ROS (Wagner et al., 2008). It appears 
that this relationship can become disassociated under certain conditions, which makes precise prediction 
of functional outcomes from changes in gene expression difficult. Further work, beyond the scope of the 
current study will be required to further verify what, if any, the functional significance of the changes 
we have found at the level of gene expression, although they do not appear to simply reflect a simple 
alteration in the number of steady-state mitochondria due to altered biogenesis or mitophagy. We also 
can’t rule out the possibility that increased/decreased biogenesis and mitophagy together may result in 
no net change in steady-state levels of mitochondri which could explain these results. 
 
Down-regulation of the OXPHOS system in blood leukocytes is usually only associated with their 
migration to the site of tissue damage or pathogen invasion accompanied by their differentiation and 
activation during acute inflammation (Saeed et al., 2014). However, recent data suggests in chronic re-
exposure to stimuli, down-regulation of OXPHOS may be also observed in circulating cells such as 
monocytes as a result of epigenetic re-programming or trained immunity which enable them to respond 
more readily to re-stimulation (Netea et al., 2016; Saeed et al., 2014). Such cells activate a metabolic 
switch to glycolysis that not only provides substrates for biosynthetic programs, maintains mitochondrial 
membrane potential and provides energy in the form of ATP to the cell in oxygen depleted environments 
during an inflammatory response, but also generates significant ROS which has important bactericidal 
benefits (O'Neill and Hardie, 2013). Our results may reflect a systemic and general response to a chronic 
pro-inflammatory environment in the brain found in many neurodegenerative diseases, including AD. 
















OXPHOS system resulting in an excess of electrons available to react with dioxygen which then 
produce unstable and damaging free radicals (ROS) (Sena and Chandel, 2012). Unchecked ROS can 
damage biomolecules in their vicinity and for this reason Complex I, III and IV are particularly 
vulnerable (Musatov and Robinson, 2012). Complexes I and IV have previously been shown to have 
lower subunit expression or activity in AD brain (Kish et al., 1992; Leutner et al., 2005; Maurer et al., 
2000; Mutisya et al., 1994) and in peripheral blood cells in AD (Bosetti et al., 2002; Parker et al., 1990). 
Changes in Complex IV are believed to have significant knock-on effects on Complex I, which not only 
produces the majority of ROS, but is itself particularly vulnerable to ROS (Musatov and Robinson, 
2012). These changes may also contribute to the oxidative inactivation of m-aconitase observed in blood 
and brain which is a source of Fe2+ and H2O2 and believed to be a contributing factor to neurotoxicity in 
AD (Mangialasche et al., 2015).  
 
We did not find an increase in mitochondrial steady state levels to explain the changes in gene 
expression we observed. The selective increase in levels of OXPHOS subunits from the mitochondrial 
genome were more likely to result from a block at the level of translation as large numbers of nuclear 
encoded mitochondrial ribosome genes (MRP genes) required for their translation were also down-
regulated in MCI and AD, whilst there were no changes in nuclear-encoded genes required for their 
transcription. Furthermore, we observed selective increases in adjacent genes, particularly those which 
lay close to the mtDNA transcriptional start site and/or are post-transcriptionally processed together 
following initial transcription as a single polycistronic heavy chain transcript (Figure S1). OXPHOS 
genes from the mitochondria can only be transcribed on one of two polycistronic transcripts. The 
changes appear therefore to have arisen after transcription and probably represent selective transcript 
turnover, perhaps in response to a translational block contributed by the lower expression of MRP genes 

















Recessive mutations in 16 of the 84 nuclear and 13 mitochondrial OXPHOS genes are associated with 
brain disorders characterized by symptoms of dementia, including many of the genes altered in the 
present study (Fattal et al., 2006; Koopman et al., 2013). Interestingly Complex II is the only OXPHOS 
complex where all subunits are synthesised by the nuclear genome and where we did not see any 
difference in MCI or AD blood. A study investigating regional differences in the expression of nuclear-
encoded OXPHOS genes in AD brain showed this was the only complex to show no decrease in 
expression in the entorhinal cortex, a region of the brain affected relatively early in disease (Liang et al., 
2008). This complex has however been shown to be reduced in Parkinson’s disease (PD) white blood 
cells (Yoshino et al., 1992) suggesting there may be disease specific changes. 
 
The overall process of oxidative phosphorylation is tightly controlled by transcriptional regulation at the 
level of DNA and RNA, by substrate feedback inhibition and by post-translational modifications 
including phosphorylation and acetylation. Inefficient electron transfer through complexes I-IV leads to 
various human abnormalities, which is due in part to a loss of energy metabolism and a deregulation of 
critical enzymes, such as complexes I, II and III. Without proper regulation, the production of ROS is 
known to increase. Some diseases associated with impaired OXPHOS include diabetes, PD, AD, cancer 
and the aging process itself. Many diverse classes of drugs inhibit OXPHOS and induce mitochondrial 
toxicity. Not surprisingly, the ability to monitor the expression levels of the OXPHOS complexes is a 
key element in the study of many diseases and to the process of drug safety evaluation and to monitor 
drugs which may have beneficial effects in AD. 
 
Overall, our findings suggest a change in OXPHOS in mitochondria from people with MCI and AD, 
















mitophagy. The decreased expression of nuclear-encoded OXPHOS and MRP genes in MCI and AD 
was accompanied by an increase in mitochondrial-encoded OXPHOS genes in a pattern suggesting a 
selective block in their translation. These changes in OXPHOS genes are expected to drive a negative 
feedback loop that further reduces mitochondrial translation (Nolden et al., 2005).  
 
5.0 CONCLUSIONS 
Changes in OXPHOS appear before a clinical diagnosis of AD in blood. It isn’t clear whether they lead 
to maladaptive functional consequences, or merely reflect changes occurring in AD brain and have no 
functional consequences of their own. Our findings, which mirror some of the changes occurring in the 
brain, could support efforts to identify compounds or genes upstream which may co-ordinately regulate 
OXPHOS gene expression in efforts to mitigate potentially harmful downstream ROS production. 
Further work would be needed to confirm and refine these pathways in the brain and blood, but 
ultimately our results could be used for assessing drug efficacy for target development and for 
monitoring effects using ex vivo blood cell assays or analysis of blood in vivo. 
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Table 1: Subject characteristics of individuals used in the study. In total 370 individuals had genome-wide expression data generated in leukocytes using 
the Illumina HT-12 V4 expression beadarray. For the purposes of the current manuscript only the 240 nuclear-genome expressed probes relating to 
mitochondrial function were analysed. Quantitative Real-Time PCR (qRT-PCR) was used to measure gene expression levels of 12 mitochondrial-genome 
expressed transcripts in 509 individuals. This included 181 of the 370 individuals for whom genome-wide expression data is presented in this manuscript, and 
an additional 272 of the 329 individuals for whom we previously published genome-wide expression data (Lunnon et al, 2012; Lunnon et al, 2013 - Batch 1). 
Luminex was used to quantify levels of functional electron transport chain proteins in a subset of 70 individuals for whom both beadarray and qRT-PCR data 
was generated. Finally qRT-PCR was used to assess mitochondrial DNA copy number in 87 individuals, that also had beadarray and qRT-PCR data generated. 





Illumina HT-12 V4 Arrays (batch 2) qRT-CR Protein mtDNA 
Control MCI AD Control MCI AD Control MCI AD Control MCI AD 
Samples analysed 129 109 132 177 168 164 27 19 24 28 31 28 
Gender (M/F) 52/77 48/61 50/82 73/104 77/91 55/109 12/15 9/10 11/13 12/16 13/18 11/17 
Age in years (Mean±SD) 75.2 (5.8) 78.5 (7.7) 77.8 (6.7) 73.6 (7.0) 74.7 (6.4) 76.8 (6.5) 82.4 (2.7) 82.2 (1.2) 82.0 (2.5) 77.5 (7.7) 77.0 (6.9) 80.3 (4.6) 
MMSE (Mean±SD) 28.3 (3.8) 26.6 (3.5) 20.2 (5.9) 28.9 (1.3) 27.1 (1.9) 20.8 (4.5) 28.3 (1.6) 26.7 (1.9) 20.2 (4.5) 29.1 (1.0) 27.3 (1.8) 20.1 (4.6) 













ACCEPTED MANUSCRIPTTable 2: Expression of many nuclear-genome encoded OXPHOS genes, mitochondrial ribosomal protein 
(MRP) genes and mitochondrial transcriptional regulator genes are decreased in Alzheimer’s disease. The 
240 probes on the Illumina HT-12 V4 expression beadarray corresponding to OXPHOS genes, MRP genes and 
mitochondrial transcription were selected for analysis. Data was adjusted for co-variates such as age, sex, centre 
and RIN and subsequently analysed using one-way ANOVA to assess the relationship between disease group and 
expression levels. Data was corrected using the Benjamini Hochberg method for multiple testing and only data 
with an FDR q<0.01 was deemed significant. For data with q<0.01 post-hoc t-tests were performed to assess 
differences between groups. Genes highlighted in bold have previously been shown to contain recessive 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3: qRT-PCR was used to determine the differences in expression of genes expressed from the mitochondrial genome in blood samples from 
control, MCI and Alzheimer’s disease. Data is shown graphically in Figure 1.  Regression p values and post-hoc t-tests were corrected for multiple testing 























































































































Complex V MT-ATP6 21.88 500 0.000004 2.24E-05 ↑ 0.000009 0.000046 ↑ 0.000005 4.05E-05 ↑ 0.850000 8.74E-01 














Figure 1: Differences in expression of mitochondrial genome genes in circulating white blood 
cells in control (CTL, n=177), MCI (n=168) and AD (n=164). qRT-PCR  was used to determine 
the difference in the expression levels of MT-ND1 (A), MT-ND2 (B), MT-ND3 (C), MT-ND4 (D), 
MT-ND4L (E), MT-ND5 (F), MT-ND6 (G), MT-CYB (H), MT-CO1 (I), MT-CO2 (J), MT-CO3 (K) 
and MT-ATP6 (L) in control (CTL),  MCI and AD samples. Linear regression demonstrated between 
group differences for ND1 (F=12.90; p=3.61x10-4; q=1.08x10-3), ND3 (F=5.41; p=0.0204; 
q=0.0396), ND6 (F=5.19; p=0.0231; q=0.0396), CO1 (F=36.45 p=3.05x10-9; q=3.66x10-8), CO2 
(F=21.04; p=5.69x10-5; q=2.28x10-5), CO3 (F=9.479; p=2.19x10-3; q=5.26x10-3) and ATP6 
(F=21.88; p=3.73x10-6; q=2.24x10-5). Regression p values and post-hoc t-tests were corrected for 
multiple testing using the Benjamini-Hochberg method (correcting for 12 ANOVA tests and 
subsequently 36 t-tests). Full data is provided in Table 3. Key: *=p<0.05; **=p<0.01; ***=p<0.005 



















































• Decreased OXPHOS and mitochondria ribosome nuclear genes in Alzheimer’s disease blood 
• Increased OXPHOS mitochondrial genes in Alzheimer’s disease blood 
• Changes appear to be independent of mitochondrial biogenesis or mitophagy 
• OXPHOS efficiency may be compromised leading to damaging reactive oxygen species 
